Shares of Athersys, Inc. (NASDAQ:ATHX) have earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price objective of $9.00 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given Athersys an industry rank of 161 out of 265 based on the ratings given to related companies.

Several equities analysts have recently commented on the company. Maxim Group set a $9.00 price target on Athersys and gave the company a “buy” rating in a research note on Tuesday, May 16th. William Blair reissued an “outperform” rating on shares of Athersys in a report on Tuesday, March 28th. Finally, Zacks Investment Research raised Athersys from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Tuesday, March 14th.

In other Athersys news, EVP John J. Harrington sold 36,000 shares of the business’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $1.45, for a total transaction of $52,200.00. Following the transaction, the executive vice president now owns 712,743 shares of the company’s stock, valued at $1,033,477.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.90% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in ATHX. Bank of America Corp DE raised its position in Athersys by 17.2% in the first quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 9,019 shares during the last quarter. Oxford Asset Management bought a new stake in shares of Athersys during the fourth quarter valued at $105,000. Wells Fargo & Company MN increased its stake in shares of Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,800 shares during the period. TFS Capital LLC bought a new stake in shares of Athersys during the first quarter valued at $149,000. Finally, FNY Partners Fund LP bought a new stake in shares of Athersys during the first quarter valued at $206,000. 17.73% of the stock is currently owned by institutional investors and hedge funds.

Athersys (NASDAQ ATHX) opened at 1.58 on Friday. The stock’s market capitalization is $175.88 million. Athersys has a 1-year low of $1.02 and a 1-year high of $2.35. The firm’s 50 day moving average is $1.46 and its 200 day moving average is $1.40.

Athersys (NASDAQ:ATHX) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The company had revenue of $1.50 million during the quarter, compared to the consensus estimate of $0.45 million. Athersys had a negative return on equity of 135.04% and a negative net margin of 765.65%. Athersys’s revenue was down 90.3% on a year-over-year basis. During the same period last year, the company earned $0.06 earnings per share. On average, equities research analysts anticipate that Athersys will post ($0.26) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Athersys, Inc. (ATHX) Receives Consensus Recommendation of “Strong Buy” from Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get a free copy of the Zacks research report on Athersys (ATHX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with's FREE daily email newsletter.